Biotech · Private company

COUR Pharmaceutical Development Company, Inc.

Track this companyFree. Adds COUR Pharmaceutical Development Company, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials72 recruiting or active

Pipeline programs4From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline4

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)PHASE1_PHASE2 · RECRUITING · started May 12, 2025ClinicalTrials.gov NCT06783309 · fetched Nov 12, 2026
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia GravisPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 30, 2024ClinicalTrials.gov NCT06106672 · fetched Nov 12, 2026
CNP-201 in Subjects With Peanut AllergyPHASE1 · TERMINATED · started Mar 14, 2022ClinicalTrials.gov NCT05250856 · fetched Nov 12, 2026
Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary CholangitisPHASE1_PHASE2 · COMPLETED · started Jan 25, 2022ClinicalTrials.gov NCT05104853 · fetched Nov 12, 2026
Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut AllergyPHASE1 · TERMINATED · started Jun 2, 2021ClinicalTrials.gov NCT04950504 · fetched Nov 12, 2026
Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac DiseasePHASE2 · COMPLETED · started Nov 11, 2018ClinicalTrials.gov NCT03738475 · fetched Nov 12, 2026
Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac DiseasePHASE1 · COMPLETED · started Jan 23, 2018ClinicalTrials.gov NCT03486990 · fetched Nov 12, 2026